ONCAlert | Upfront Therapy for mRCC
Latest From Society of Hematologic Oncology
Targeted Oncology Welcomes the Society of Hematologic Oncology to Its Strategic Alliance Partnership Program
2:30 PM, Wed January 8, 2020
Real-World Data Show Tisagenlecleucel is an Effective Treatment for DLBCL
12:50 AM, Sun September 15, 2019
More Research and Development on JAK Inhibition May Improve Myelofibrosis Management
9:00 PM, Sat September 14, 2019
Safety Profiles of Ruxolitinib and Fedratinib in Myelofibrosis
10:34 PM, Fri September 13, 2019
Phase II JULIET Study Continues To Show Benefit of Tisagenlecleucel in DLBCL
9:11 PM, Fri September 13, 2019
Improvement in PFS Shown With Checkpoint Inhibition Before Transplantation in R/R Hodgkin Lymphoma
6:30 PM, Fri September 13, 2019
Fedratinib Approval Further Validates JAK Inhibition for Myelofibrosis Treatment
4:21 PM, Fri September 13, 2019
Ruxolitinib Used to Prevent GVHD Throughout Stem Cell Transplantation
11:59 PM, Thu September 12, 2019
Expert Suggests Novel Approaches To Improve CAR Therapies in ALL
10:23 PM, Thu September 12, 2019
Dose Modifications to Duvelisib Do Not Compromise Outcomes in R/R CLL/SLL
6:44 PM, Thu September 12, 2019